EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Editorial: Pathogenic Neisseria: Pathogenicity, vaccines, and antibiotic resistance

Jesús Arenas

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2022.1119244 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Jesús Arenas. Beteiligte Einrichtung: Unit of Microbiology and Immunology, Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain. Hauptthemen laut MEDLINE: Neisseria meningitidis, Vaccines. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EDITORIAL article Front. Cell. Infect. Microbiol., 05 January 2023Sec. Molecular Bacterial Pathogenesis Volume 12 - 2022 | https://doi.org/10.3389/fcimb.2022.1119244

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neisseria meningitidisVaccinesNeisseriaVirulenceNeisseria gonorrhoeaeDrug Resistance, Microbial

Stichwörter der Autor:innen

Neisseria gonorrhoeaeNeisseria meningitidisantibiotic resistancebacteria competitionmafA/B systemtwo partner secretion systemvaccines

Substanzen

Vaccines

Autor:innen und Institutionen

  • Unit of Microbiology and Immunology, Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain.

Zitieren

APA

Arenas, J. (2023). Editorial: Pathogenic Neisseria: Pathogenicity, vaccines, and antibiotic resistance. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2022.1119244

Vancouver

Arenas J. Editorial: Pathogenic Neisseria: Pathogenicity, vaccines, and antibiotic resistance. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2022.1119244

BibTeX
@article{Arenas2023,
  author = {Arenas, Jesús},
  title = {Editorial: Pathogenic Neisseria: Pathogenicity, vaccines, and antibiotic resistance},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2022.1119244}
}
Kostenlos starten →